Regulatory

June 13, 2025

Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study

Solna, Sweden, June 13, 2025. Affibody’s licensee Rallybio Corporation (Rallybio) has announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, an innovative, once-weekly,...

Read more

Regulatory

May 27, 2025

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 27, 2025 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

Regulatory

April 25, 2025

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Tuesday...

Read more

Regulatory

December 10, 2024

Affibody’s Licensee ACELYRIN Announces Top-line Results for Izokibep in Uveitis

Stockholm, Sweden, December 10, 2024. Affibody’s licensee ACELYRIN, INC. today announced that the Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint. Izokibep...

Read more

Regulatory

August 13, 2024

Positive Phase 3 Results in Hidradenitis Suppurativa Further Strengthen Competitive Profile of Izokibep

• Phase 3 trial of izokibep in patients with hidradenitis suppurativa met primary endpoint of HiSCR75 at week 12, as well as the key secondary endpoints of HiSCR90 and...

Read more

Regulatory

May 16, 2024

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 16, 2024 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

Regulatory

April 19, 2024

Affibody publishes Annual Report 2023

Stockholm, Sweden, April 19, 2024. Affibody Medical AB (publ) today announced that the Annual Report for 2023 now is available at the company’s website, and as an attachment to...

Read more

Regulatory

March 26, 2024

First gastroesophageal cancer patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

Solna, Sweden, March 26, 2024. Affibody AB (“Affibody”) today announced that the first patients with gastroesophageal cancer have been dosed in a Phase 2 clinical basket study of the...

Read more

Regulatory

March 11, 2024

Affibody’s Partner ACELYRIN Announces Positive Top-line Results for Izokibep in Psoriatic Arthritis and Long-Term Clinical Benefits in Hidradenitis Suppurativa

Phase 2b/3 psoriatic arthritis clinical trial met the primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance. Robust responses were achieved for ACR70, PASI100, ACR50/PASI100,...

Read more